Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market

Medicus Pharma Ltd (MDCX)

The global population is aging rapidly, with the number of people aged 65 and older expected to double by 2050. This demographic shift is driving a surge in chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. At the same time, breakthroughs in biomedical research are enabling the development of targeted, more effective therapies, transforming treatment approaches in both human and veterinary medicine. These twin forces, rising demand fueled by aging and disease prevalence along with technological innovation, are propelling unprecedented growth across biopharma markets. The global biotechnology sector is projected to expand from $1.74 trillion in 2025 to over $5 trillion by 2034, representing a compound annual growth rate (CAGR) of 12.5 percent. Specialty pharmaceuticals, including biologics and novel drug delivery systems, are expected to grow even faster, with forecasts predicting a 26.5 percent CAGR over the same period. Oncology remains a key driver, with spending on cancer medicines forecasted to nearly double from $252 billion in 2024 to $441 billion by 2029. Meanwhile, veterinary oncology is emerging as a high-potential frontier, with the U.S. market alone projected to reach $1.48 billion by 2030, driven by rising pet ownership and demand for advanced care. The urology therapeutics segment also shows steady growth potential, expected to rise from $10.5 billion in 2024 to $15.8 billion by 2033. Amid this expansive and interconnected landscape, Medicus Pharma Ltd. (NASDAQ: MDCX) is methodically positioning itself to capitalize on these powerful market tailwinds. Through a diversified portfolio of innovative drug delivery platforms and targeted therapies, Medicus addresses some of the most pressing health challenges across human and veterinary medicine. Medicus Pharma: Methodically Building a High-Leverage Growth Story Though still flying under many investors’ radars, Medicus Pharma is rapidly assembling the elements of a high-leverage growth story. On June 2, the company completed a $7 million public offering, selling 2,260,000 units at $3.10 each. Each unit includes one common share plus one warrant exercisable at the same price over five years. The capital will primarily fund a Phase 2 proof-of-concept trial in basal cell carcinoma (BCC) using Medicus’s flagship doxorubicin-loaded dissolvable microneedle patch (D-MNA). Additional funds may support broader development in non-melanoma skin cancers or other pipeline programs. Strategic Veterinary Expansion: FDA Submission for Equine Squamous Cell Carcinoma This timely financing was quickly followed by a major regulatory milestone. On June 9, Medicus announced submission of a formal product development plan to the U.S. FDA for a veterinary application of D-MNA targeting equine squamous cell carcinoma (SCC). The program is advancing under an Investigational New Animal Drug (INAD) file, aiming for conditional approval. It leverages the same microneedle patch technology used in human dermatologic trials, demonstrating a strategic effort to repurpose clinical data and technology across human and veterinary markets. Tapping an Untapped Veterinary Oncology Opportunity The equine indication represents a significant market opportunity. As CEO Dr. Raza Bokhari highlighted, “In veterinary medicine, where only a handful of oncology drugs are approved, developing a non-invasive treatment for equine SCC targets a largely unmet need, a potential $250 million market.” The planned study will enroll 50 horses across five U.S. sites in a placebo-controlled design, comparing two D-MNA doses against placebo, with tumor response assessed at day 90. Medicus has secured FDA Minor Use in Major Species (MUMS) Designation, which grants seven years of market exclusivity upon approval, a valuable commercial advantage in a segment with limited competition. D-MNA Platform: Promising Safety and Efficacy Data The D-MNA patch, originally developed for human skin cancers, is supported by encouraging early data. A Phase 1 trial in Australia (SKNJCT-001) involving 13 patients with nodular BCC showed the treatment was well tolerated with no dose-limiting toxicities. Remarkably, 46 percent of lesions achieved complete histological clearance after a single application, an impressive result given the minimally invasive delivery. This platform delivers doxorubicin directly into the dermis through a biodegradable microneedle array, minimizing systemic exposure while concentrating the drug’s effect at the tumor site. Expanding Clinical Trials Across Continents Building on this foundation, Medicus is running two Phase 2 trials. In the U.S., the SKNJCT-003 study recently expanded enrollment from 60 to 90 patients following a positive interim analysis that showed over 60 percent clinical clearance. This multicenter, placebo-controlled trial compares the patch to the standard of care, with European sites now joining due to growing investigator interest. Concurrently, the SKNJCT-004 trial in the United Arab Emirates involves 36 patients across four hospitals, including Cleveland Clinic Abu Dhabi, targeting both histological and clinical clearance endpoints. Strategic Acquisition: Entering Late-Stage Urology Complementing its internal pipeline, Medicus is also positioning itself as a consolidator of high-value assets. In April, the company signed a binding letter of intent to acquire UK-based Antev Ltd., whose lead candidate, Teverelix, is a GnRH antagonist in late-stage development for two urology indications: acute urinary retention (AUR) due to benign prostatic hyperplasia and hormone-sensitive prostate cancer in patients at elevated cardiovascular risk. These combined markets represent a $6 billion annual opportunity, and Teverelix has completed multiple clinical trials in Europe. Under the deal, Antev shareholders would receive approximately 19 percent of Medicus’s post-merger equity, plus up to $65 million in milestone payments tied to regulatory and commercial successes. A Platform With Multiple Growth Levers Together, Medicus offers optionality and platform leverage across human oncology, veterinary medicine, and dermatology, all fields marked by limited innovation and strong pricing power. Its lead asset is already in Phase 2 with international trial sites and active FDA engagement. The veterinary program offers a faster commercialization path with fewer regulatory barriers, while the Antev acquisition could propel Medicus into late-stage, multi-billion-dollar indications. Why Investors Should Watch MDCX Medicus Pharma (NASDAQ: MDCX) paints the picture of a small-cap biotech transitioning from concept to execution. The recent capital raise was non-dilutive and immediately followed by a key regulatory filing. Clinical trials across humans and animals are expanding, and a transformative acquisition is imminent. With a methodical approach tying together clinical progress, intellectual property, and market strategy, Medicus is quietly building momentum, making MDCX a stock to watch closely in the second half of 2025. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by MDCX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 10, 2025 10:20 AM Eastern Daylight Time

HPS and PayMedix Partner with Gravie to Expand Access and Simplify Healthcare Payments

PayMedix

MILWAUKEE, WI – June 10, 2025 – PayMedix, a leading healthcare financing and payments solution, and HPS, one of Wisconsin’s largest independent provider networks, today announced a strategic partnership with Gravie, a health benefits company reimagining health plans for small and midsize businesses. As a result of this partnership, eligible Gravie members will gain access to the comprehensive HPS provider network and benefit from the transparency and ease of the PayMedix payment platform. The collaboration reflects a shared commitment between Gravie, HPS, and PayMedix to help reshape the healthcare experience with solutions that prioritize improved access and member well-being. "This partnership represents a fundamental shift in how regional employers can approach healthcare benefits," said Brian Marsella, President of HPS and PayMedix. "Gravie's mission to make health benefit plans work for everyone is well-aligned with our vision to make healthcare more affordable and accessible for all. By combining Gravie's level-funded approach with our comprehensive network and payment solutions, we're creating new possibilities for employers to transition from traditional fully-insured arrangements to more flexible, cost-effective plan designs." Through this partnership, eligible Gravie members will gain access to HPS's Wisconsin provider network, which includes over: 100 hospitals 30,000 physicians 1,200 clinics 630 behavioral health providers Members will also benefit from PayMedix, a healthcare payment experience that simplifies the billing process. PayMedix pays contracted providers in full and consolidates all medical billing into one clear, monthly statement, the SuperEOB ®, which displays all charges, insurance payments, and patient balances into a single view. To make healthcare even more accessible for everyone, PayMedix offers interest-free financing and flexible repayment plans to all members for all allowed in-network expenses up to their out-of-pocket maximum, with no credit check required, removing a common barrier to care and delivering financial peace of mind. "At Gravie, we're constantly seeking innovative ways to improve our members' healthcare experience," said Evan Peters, SVP of Networks at Gravie. "Partnering with HPS and PayMedix allows us to offer greater access to high-quality regional care while removing financial barriers that too often prevent people from getting the care they need. This partnership represents another exciting step toward making healthcare work better for Wisconsin families." ___________________________________ About Health Payment Systems (HPS) HPS is a privately held healthcare technology and services organization with solutions that reduce the cost and complexity of the healthcare payments process to benefit providers, employers, patients, and TPAs. Headquartered in Milwaukee, Wisconsin, HPS has an independent network of 100+ hospital facilities and 30,000+ individual providers. About PayMedix PayMedix is the only company solving the problem of high out-of-pocket costs for everyone –providers, employers, patients, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and interest-free financing for all patients. PayMedix has processed over $6 billion in medical payments for hospital systems and physician practices and can overlay any provider network. About Gravie Gravie is the only health benefits company bringing both level-funded and ICHRA health plans to small and midsize employers. Comfort ®, Gravie’s flagship product, is the nation’s first-of-its-kind health plan that provides first-dollar, no-cost coverage on most common healthcare services, at a cost comparable to traditional group health plans. Contact Details Hattie Ninteau hninteau@hps.md Company Website https://paymedix.com

June 10, 2025 10:00 AM Eastern Daylight Time

Shumate Engineering Presents Breakthrough Hybrid Dry Adiabatic Cooling Design, Passes Key Benchmark

The Hoyt Organization

In a major breakthrough for the data center industry, Shumate Engineering, a leading full-service MEP engineering firm specializing in mission-critical data center environments, has launched its new cooling design, which is proven to significantly reduce power and water consumption. Hybrid-Dry/Adiabatic-Cooling (HDAC), a patent-pending design, was presented last month at AFCOM’s Data Center World conference in Washington, D.C., to hundreds of industry insiders who agreed with the system. HDAC utilizes both wet and dry cooling techniques within a closed loop, has the potential to disrupt the sector – just as its grappling with the proliferation of artificial intelligence. “With the need for massive computing power taking hold around the world, the data center industry is booming right now; however, the power and water needed to cool the racks and keep them functioning has limited its progress,” said Daren Shumate, PE, founder and managing principal of Tysons, Va.-based Shumate Engineering. “Major data center projects backed by the biggest names in tech have resorted to drastic measures to meet this demand, including the construction of high-density data centers that span city blocks and recommissioning nuclear power plants, but our cooling design manages to use half of the power and less than 10 percent of the water compared to traditional data centers – offering a massive savings of natural resources and billions of dollars in costs.” This hybrid-dry adiabatic (HDAC) design was presented by Shumate and R. Stephen Spinazzola, PE, director of mission critical services at Shumate Engineering at the AFCOM conference. They explained how to get power usage effectiveness (PUE) for a hyperscale data center in the mid-Atlantic region – typically higher than 1.2 – down to a range between 1.1 to 1.06 PUE, depending on the ratio of traditional air cooled versus direct liquid cooled equipment. They followed up the presentation with a successful test at Baltimore Aircoil Company's testing facility where the system met all specific design requirements, including: Maintaining 68 deg F fluid supply temp up to 60 deg F ambient dry bulb Maintaining 90 deg F fluid supply temp up to 82 deg F ambient dry bulb Maintaining 90 deg F fluid supply temp up to 81 deg F ambient wet bulb “We are incredibly pleased with the performance of our HDAC design,” said Spinazzola, the creator of the design who already has six patents in his name. “This test verifies our claim that this system uses approximately the same water an air-cooled chiller system uses when combining on site and electrical power plant water use.” The timing couldn’t be more relevant. As global demand for high-performance data centers surges — driven largely by the exponential growth of artificial intelligence, machine learning, and cloud computing — cooling infrastructure has become a critical bottleneck. Shumate Engineering's groundbreaking solution addresses both the energy and environmental challenges associated with traditional evaporative and mechanical cooling methods. “Our new hybrid system is a game-changer,” Shumate said. “By dramatically reducing both energy and water consumption, we're enabling data center operators to scale up AI and high-density workloads sustainably and cost-effectively. It’s an engineering solution that meets the moment.” Unlike conventional systems that rely heavily on water-based evaporative cooling, Shumate Engineering’s HDAC design combines advanced dry cooling principles with prescribed adiabatic enhancements, optimizing thermal performance without compromising environmental responsibility. The result is a scalable, modular system that not only meets the intense thermal demands of AI-driven computing but also reduces operational costs and environmental footprint — a critical consideration as data centers face growing scrutiny over resource usage. “Considering that a typical ChatGPT query used 10 times more power than the average Google search, the future of computing demands a future-ready infrastructure,” Spinazzola said. “Our HDAC system keeps pace with technological advancements while meeting aggressive sustainability goals – cutting power usage in half and using just a sip of water." About Shumate Engineering Shumate Engineering is a full-service MEP engineering firm specializing in mission critical, data center environments. Its ever-growing roster of engineers have collaborated on many projects — from the namesakes of northern Virginia’s “Data Center Alley” and the rapidly growing DMV housing market to new prospects in Richmond and beyond. The team’s game-changing Hybrid Adiabatic Fluid Cooler - which uses half as much power and 90 percent less water than traditional cooling systems for AI data centers - is set to be approved by the U.S. Patent and Trademark Office this summer. Learn more at shumateengineering.com. Daren Shumate, Founder and Managing Principal of Shumate Engineering, boasts many accomplishments in data center design including is an engineering icon the Smithsonian Institution’s main data center in Herndon, eBay’s chief 26-megawatt Tier E structure in Utah, the NSA’s High Performance Computing Center in Ft. Meade, and the Fannie Mae-owned data center in Urbana that was the first of its kind to attain LEED. He is a licensed electrical engineer in more than 20 states and lives in the Washington, D.C. area. Steve Spinazzola, Director of Mission Critical Services for Shumate Engineering, offers more than 42 years of experience in both mechanical design and project management on corporate, mission-critical, educational, health and science, retail, and institutional projects. His game-changing Hybrid Adiabatic Fluid Cooler - which uses half as much power and 90 percent less water than traditional adiabatic cooling - is set to be approved by the U.S. Patent and Trademark Office this summer. ### Contact Details Shumate Engineering Andrew King +1 914-513-6895 aking@hoytorg.com Company Website https://shumateengineering.com

June 03, 2025 04:01 PM Eastern Daylight Time

CURE ALZHEIMER’S FUND APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund, a nonprofit dedicated to advancing research with the highest potential to prevent, slow or reverse Alzheimer’s disease, announced today that Christine Villas-Boas and Brittany Bowlen have been appointed to its Board of Directors. “We are pleased to welcome two new voices to our Board—Christine and Brittany each bring a unique passion and perspective that will help us better serve our mission to fund research aimed at curing Alzheimer’s disease,” said Henry McCance, Board Chair and Co-Founder of Cure Alzheimer’s Fund. “This expansion of our board is a meaningful step forward as we continue to grow thoughtfully and stay focused on making a lasting impact on the fight against this devastating disease.” “Brittany and Christine bring outstanding leadership expertise and a clear passion for our cause,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Their diverse experience in strategy and commitment to impactful philanthropy will enhance our efforts to accelerate critical research. We’re excited to welcome their insight and energy to our board.” Christine Villas-Boas currently serves as President and Treasurer of the Michel and Claire Gudefin Family Foundation, a leading supporter of Cure Alzheimer’s Fund. Ms. Villas-Boas, a Connecticut College graduate, began her career at Chase Manhattan Bank in 1974, working in U.S. Corporate Banking and International Capital Markets across New York, Paris, and London. She later consulted in credit and corporate finance training. Ms. Villas-Boas also serves on the board of the Learn2Earn Charitable Foundation based in Naples, Florida. Inspired by personal loss—her mother Claire, who died of Alzheimer’s in 2015, and other family members affected by the disease—Christine and the Michel and Claire Gudefin Family Foundation are deeply committed to supporting Cure Alzheimer’s Fund in its mission to find a cure. She became a Trustee in 2021 and joined the Board of Directors in 2025. Brittany Bowlen is a seasoned leader in consulting and professional sports, most recently serving as the Senior Vice President of Strategy for the Denver Broncos. In addition to her professional career, Brittany is deeply committed to driving community impact, currently serving as the Vice Chair of the Board of Directors for Boys & Girls Clubs of Metro Denver and as a member of the Board of Visitors for Duke University’s Fuqua School of Business. She holds a Master of Business Administration (MBA) from Fuqua and a Bachelor of Business Administration (BBA) from the University of Notre Dame’s Mendoza College of Business. Cure Alzheimer’s Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided 971 grants to more than 300 of the world’s leading researchers and contributed more than $232 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has achieved a 100% perfect score and a Four-Star rating for 13 consecutive years from Charity Navigator. Cure Alzheimer’s Fund also received a Platinum Seal of Transparency from Candid, formerly known as GuideStar. Our Board of Directors, Trustees and a core group of other donors direct their donations to our overhead expenses so that 100% of general donations go to our research program. For more information, visit CureAlz.org. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website http://curealz.org

June 03, 2025 08:41 AM Eastern Daylight Time

CONSENSUS HEALTH’S ARNOLD PALLAY, MD FAAFP SELECTED AS A 2025 HEALTHCARE HERO BY NJBIZ MAGAZINE

Consensus Health

Consensus Health, a leading New Jersey-based healthcare organization with a physician-led medical group and an Independent Physician Alliance (IPA), announced today Arnold Pallay, MD FAAFP, practicing physician and medical director, was named a 2025 Healthcare Hero by NJBIZ Magazine, a leading business journal covering New Jersey. The Healthcare Heroes Awards program was created to recognize excellence, promote innovation and honor the efforts of individuals and organizations making a significant impact on the quality of health care throughout New Jersey. Submissions are reviewed and winners chosen by a panel of independent judges. The 2025 program recognized individuals and organizations across 10 categories. For nearly 40 years, Dr. Pallay has been a practicing family physician in the Montville, New Jersey community. In fact, he serves as volunteer president of the Montville Township Board of Health. Additionally, Dr. Pallay was chosen as the population health executive medical director for Partners In Care, the oldest IPA in New Jersey. Throughout his career, Dr. Pallay also garnered distinctive expertise in connective tissue, cardiac, neurodegenerative and pharmacogenetics (practiced by only a handful nationwide), prompting patients to travel from afar after experiencing struggles in their diagnoses and care. In all these roles, Dr. Pallay influences thousands of patients’ lives by assuring their top-notch quality care. “Having been selected as a 2025 Physician of the Year by NJBIZ is an exceptional and prestigious honor I am humbled to accept. Throughout my entire career, I have dedicated my practice to caring for generations of New Jersey families, and this award speaks volumes to the commitment I chose and my effects on local patient care. I thank the judges for acknowledging me, my patients for entrusting me and the Consensus Health Medical Group team for both recognizing and nominating me,” Dr. Pallay said. Michael Lovett, Consensus Health president and chief executive officer, added: “Dr. Pallay, one of the first physicians to join our medical group, has been impacting the health of New Jersey citizens for nearly four decades. During this time, he has excelled in his focus, always expanding his horizons to elevate care for families. All Consensus Health’s colleagues extend our deepest congratulations to Dr. Pallay on this prominent recognition and thank him for his unrelenting commitment to our patients.” NJBIZ Healthcare Heroes honorees will be recognized during an in-person awards ceremony on Tuesday, June 24 th, 8:00 AM – 10:30 AM at The Palace at Somerset Park in Somerset, NJ. Accompanying the event will be a publication supplement highlighting their accomplishments. The supplement will be inserted into the June 30, 2025 issue of NJBIZ. About Consensus Health Marlton, New Jersey-based Consensus Health is a leading physician-owned and -governed medical group comprised of New Jersey-based independent primary care providers and specialty doctors. Consensus Health affords its 172 member providers across 56 practices and 69 locations clinical autonomy, which enables them to focus on the delivery of high levels of patient care within the local markets they each serve. Currently, Consensus Health provides medical care statewide throughout 18 New Jersey counties. For more information, visit www.consensushealth.com or connect with the Company on LinkedIn. Contact Details PAIRELATIONS for Consensus Health Susan J. Turkell +1 303-766-4343 sturkell@pairelations.com Company Website https://www.consensushealth.com/

June 03, 2025 08:00 AM Eastern Daylight Time

Image

Inspira Technologies Receives $2 Price Target and Buy Rating: Everything You Need to Know

Global Markets News

Litchfield Hills Research has initiated coverage of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN)* with a Buy rating and a $2 price target, representing potential upside of over 225% from current trading levels of around $0.61 per share. This bullish outlook comes as the medical technology company continues to critical care technology addressing what the analyst describes as "a medical need without good options." The analyst notes that mechanical ventilators are "WWII technology in desperate need of an upgrade" with reports showing that 30% to 50% of ICU patients don't survive. Unlike mechanical ventilation, Inspira's ART500 technology would enable patients to remain awake during treatment while stabilizing oxygen levels without intubation and coma. What distinguishes Inspira from typical early-stage medical device companies is its proven regulatory execution and early commercial success. The company's first generation technology, the INSPIRA ART100 system, received FDA clearance in May 2024 and is already deployed in leading U.S. hospitals. The excitement around this technology reached a new high in April 2025 when the first successful patient treatment was completed at Westchester Medical Center. The commercial momentum seems to be accelerating. Inspira announced it received payment in the "low hundreds of thousands of dollars" from its U.S. distributor for delivered systems, marking the company's first revenues. CEO Dagi Ben-Noon called this "a transformative milestone for Inspira as we establish our presence in the U.S. medical landscape." The company has now initiated global commercial rollout discussions and expects additional deliveries in the second half of 2025. Central to Inspira's technology platform is the AI-powered HYLA blood sensor, which recently achieved 96% accuracy in clinical studies at Sheba Medical Center, one of the world's top hospitals. The system provides continuous monitoring without requiring blood draws, targeting the blood gas analyzer market projected to reach $5.7 billion by 2030. The analyst identifies massive market opportunities, with the global mechanical ventilators market expected to reach $20.69 billion by 2034. Inspira's flagship INSPIRA ART500 system in development aims to disrupt this market by providing respiratory support through direct blood oxygenation rather than forcing air into damaged lungs. Inspira has established strong intellectual property protection with multiple U.S. patents and novel patent claims protecting its core technologies. The company is executing a strategic approach of securing FDA clearance for individual components before integrating them into comprehensive systems. When comparing Inspira to similar medical device companies, the analyst found the stock trades at significant discounts despite having FDA-cleared technology already treating patients. The $2 price target reflects confidence in the company's ability to capitalize on its early commercial success and expand into the massive mechanical ventilation market. The analyst concludes that Inspira may represents a unique opportunity, combining proven FDA-cleared technology with substantial market opportunity and attractive valuation metrics in the high-growth medical device sector. Recent News from Inspira: Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing * Legal Disclaimer & Disclosure: Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by the Wall Street Wire platform & media network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire, which includes a monthly fee of five thousand US dollars paid in cash via bank transfer in return for promotional content and distribution services. The operators also receive additional fees for non promotional advisory and data services. Inspira Technologies did not necessarily review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here which include further details: redditwire.com/terms. We are not responsible for third party analyst price targets or market estimates are refer to them based on publicly availble reports. Additional or competing price target may exist and readers are advised to refer to the full report and its respective disclaimers and disclosures. Contact Details Wall Street Wire Editorial Desk media.globalmarkets@gmail.com

June 02, 2025 09:19 AM Eastern Daylight Time

Comcast to Connect 70,000 Homes and Businesses in Bryan-College Station to Reliable, Fiber Internet

Comcast Texas

Comcast will connect 70,000 new homes and businesses in Bryan-College Station to fast, secure and reliable, fiber Internet. This expansion into the region will enhance digital infrastructure, promote economic growth and position residents and local businesses for success in an increasingly digital world. The multi-year network expansion brings Xfinity and Comcast Business Internet, mobile, entertainment and security services to the two cities for the first time. The multiphase project includes building a new technology hub that will act as “the brain” of the network, supporting all Xfinity and Comcast Business services. Comcast will also install more than 1,000 miles of fiber lines – enough to span the distance from the Brazos Valley to Universal Studios in Florida. The tech leader also plans to open an interactive Xfinity retail store, which will be announced later. "Bryan-College Station is a hotbed for innovative technology, and this investment by Comcast will help our region stay competitive,” College Station Mayor John Nichols said. “Reliable broadband access is essential for our growing community, from the tens of thousands of Aggie students who call College Station home to our creative business community. Investing in strong connectivity ensures everyone has the advanced resources they need to thrive in a digital world." “We are grateful that Comcast is making this multimillion-dollar fiber infrastructure investment in our community,” City of Bryan Mayor Bobby Guiterrez said. “This investment in connectivity strengthens our local economy and helps our residents thrive. Expanding reliable high-speed Internet in Bryan will open doors for students, businesses and families. It will enhance opportunities and improve quality of life.” Residents can visit ComcastTexas.com/BCS for additional details on construction expectations and upcoming service availability. Portions of the project are currently under construction. Comcast’s most recent expansion to Bryan-College Station is part of the company’s $1.6 billion investment in technology and infrastructure in Texas over the last three years. “Expanding fiber Internet in communities like Bryan-College Station will be a catalyst for economic growth, enhancing educational opportunities and helping residents and businesses have the tools they need to thrive in the digital age,” Nicolas Jimenez, Comcast’s General Market Manager of Bryan-College Station said. “By investing in the infrastructure and connectivity of these communities, we’re empowering individuals and businesses to succeed and pave the way for a brighter, more connected future." A Network You Can Trust to be Reliable, Fast and Secure Comcast’s state-of-the-art network is built to enable residents and businesses to thrive in today’s constantly connected world. Bryan-College Station joins the 64 million homes and businesses across the country to have access to a network that is trusted by essential community organizations like hospitals, schools, transportation systems and first responders, and federal agencies like the Department of Defense. It delivers multi-gigabit Internet speeds, 99.9 percent reliability and security built in from the ground up to keep customers safe from cyber threats. Introducing Xfinity to Consumers Comcast’s residential services are marketed under the Xfinity brand. Consumers in Bryan-College Station will be able to take advantage of the full suite of Xfinity products: Internet, video, mobile, voice and home security. Xfinity offers multi-gigabit Internet speeds, powerful WiFi that reaches every corner of the home, and super-responsive, low-lag connections. Xfinity customers can enjoy a reliable, high-speed experience—whether they’re streaming sports and entertainment, video chatting with friends and coworkers, learning from home or simply browsing online. Comcast Business to Power Bryan-College Station’s Workforce For local businesses, Comcast Business offers a suite of connectivity, communications, networking, mobile, security, wireless, and managed solutions to help organizations of all sizes achieve their business goals. Industry analysts and associations have consistently recognized Comcast Business as a leader and innovator in flexible, scalable options as well as one of the fastest-growing providers of Ethernet services. Serving Everyone in the Bryan-College Station Community Comcast’s commitment to communities goes beyond building the network and aims to increase economic mobility for the local community and its residents. That’s why Comcast created Internet Essentials, a broadband adoption program that offers eligible households low-cost, high-speed Internet and affordable computers. Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms, we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Taisha Walker +1 832-942-1131 Taisha_Walker@comcast.com Company Website https://ComcastTexas.com/BCS

May 29, 2025 07:02 AM Central Daylight Time

Image

THE MAERCKS INSTITUTE: WHERE INNOVATION, ELEGANCE, AND ZERO-PAIN AESTHETIC SURGERY CONVERGE

The Maercks Institute

In a world where aesthetic procedures are increasingly sought after, patients are becoming more discerning—demanding not only exceptional results, but also safety, minimal downtime, and a truly elevated surgical experience. For over 15 years, The Maercks Institute in Miami has quietly set the gold standard for precisely this level of care. At its helm is Dr. Rian Maercks, a board-certified plastic surgeon with elite training from Duke University Medical Center and an international reputation for aesthetic innovation, safety, and elegance in results. Dr. Maercks’ expertise is not confined to the American academic tradition alone. His advanced surgical training and aesthetic experience span the globe—gaining exposure to the most prestigious and forward-thinking techniques across Europe, Central America, and South America. This global perspective informs his deeply nuanced understanding of beauty and anatomy across diverse cultures and aesthetic ideals, shaping the distinctive and tailored approach for which The Maercks Institute is known. Sophisticated patients from around the world turn to Dr. Maercks not only for his artistry, but for a singular promise: surgical excellence without pain, without opioids, and without the extended recoveries typically associated with aesthetic enhancement. EXAREL AND THE MAERCKS METHOD™: A BREAKTHROUGH IN PAIN-FREE, NO-DOWNTIME SURGERY The Maercks Institute offers something rarely found in aesthetic surgery today—a comprehensive array of aesthetic and corrective procedures performed with zero pain and often no need for post-operative narcotics. At the core of this revolutionary approach is Dr. Maercks’ proprietary integration of Exparel, an advanced, FDA-approved, liposomal formulation of bupivacaine that slowly releases local anesthetic over 72 hours. By combining this with his proprietary tumescent Exparel technique—which includes careful dilution, epinephrine augmentation, and a deep understanding of the gate control theory of pain—Dr. Maercks delivers procedures from deep-plane facelifts to breast augmentations with unprecedented patient comfort. Patients receive a full regional nerve block using Exparel before any incision is made. Even when general anesthesia is employed, the body is completely anesthetized locally, preventing the brain from registering pain signals both during and after surgery. The result? Patients consistently awaken feeling as though they haven't had surgery at all. They walk out of the Institute unaided, smiling, and often singing—as documented in hundreds of post-op videos at @themaercksinstitute. Remarkably, patients undergoing facelifts, body contouring, and complex revision surgeries at The Maercks Institute routinely report needing no opioids such as Percocet, no extended recovery period, and no memory of discomfort—just beautiful, natural-looking results. NATURAL REJUVENATION WITHOUT THE TELL-TALE SIGNS: THE MAERCKS LIFT As recently highlighted by the American Society of Plastic Surgeons in their article "The Mid-Facelift is Taking Facial Aesthetics by Storm", the modern patient is seeking discreet rejuvenation with minimal interruption to their lives. In response, Dr. Maercks has pioneered the MAERCKS Lift, a deep-plane midface and lower face rejuvenation technique that restores natural contours without distortion or downtime. Unlike superficial “skin pulling” methods or trendy, temporary fixes, the MAERCKS Lift works by re-supporting the deeper tissues of the face and midface along natural vectors of aging. This allows for a profoundly youthful result without the overly tight or artificial appearance seen in many conventional facelifts. Because of his innovative approach, Dr. Maercks is widely considered the go-to expert for patients desiring subtle yet significant rejuvenation. Importantly, Dr. Maercks also emphasizes holistic harmony: “A rejuvenated face must be seen in context,” he explains. “Neglecting the neck or jawline creates disharmony that patients intuitively recognize. That's why I often integrate micro-lifting or lateral platysmaplasty techniques—even in minimally invasive cases—without adding downtime or discomfort.” THE MAERCKS INSTITUTE EXPERIENCE: DISCRETION, EXCELLENCE, AND GLOBAL RECOGNITION Discerning patients seeking surgical or non-surgical facial rejuvenation, breast and body enhancement, or revision procedures find in The Maercks Institute a sanctuary of both advanced science and aesthetic artistry. With a concierge-style approach to care, elite surgical techniques, and an unwavering focus on safety and sophistication, the Institute attracts a global clientele of business leaders, public figures, and patients who value discretion and excellence. Dr. Maercks’ broad and prestigious international training through Europe, Central America, and South America allows him to draw from a uniquely diverse foundation of aesthetic understanding. This international influence has been a key driver in developing his signature techniques—each refined to prioritize safety, individuality, and natural elegance. With over 15 years in private practice, hundreds of zero-downtime success stories, and an ongoing commitment to pushing the field forward, he has earned his reputation as a trusted authority in the evolving world of plastic surgery. SCHEDULE A PRIVATE CONSULTATION For patients who value both innovation and elegance—and who are unwilling to compromise on safety or recovery—The Maercks Institute offers a uniquely refined path to self-enhancement. Discover what it means to undergo a procedure without pain, without opioids, and without sacrifice. To schedule a private consultation or learn more about our services, visit www.themaercksinstitute.com or contact the Institute directly at (305) 328-8256. Contact Details Courtney Daniels Consulting Courtney Daniels courtney@cocodaniels.com Company Website https://www.themaercksinstitute.com/

May 27, 2025 10:00 AM Eastern Daylight Time

Centre for Neuro Skills Chief Financial Officer Named 2025 Kern County Heart Walk Chair

Centre for Neuro Skills

Lindsay Ashley, chief financial officer of Centre for Neuro Skills, has been named chair of the American Heart Association ’s 2025 Kern County Heart and Stroke Walk. The annual event is scheduled for Saturday, Oct. 11, at California State University, Bakersfield. “The Kern County Heart and Stroke Walk is an opportunity to celebrate heart disease and stroke survivors, raise lifesaving funds for the American Heart Association and encourage a healthy lifestyle,” said Ashley. “By bringing the community together to raise awareness and funds to fight heart disease and stroke, we’re making strides to ensure our loved ones can live longer, healthier lives.” Ashley will lead a team of Kern County-area executives to recruit companies and organizations to take part in the Heart and Stroke Walk. The leadership team and supporting organizations will raise funds for the American Heart Association while leading action-oriented conversations about employee health, corporate engagement, community health and community transformation. The American Heart Association is the world’s leading non-profit dedicated to a world of healthier lives for all. In addition to Ashley, the 2025 Kern County Heart and Stroke Walk executive leadership team includes: David Harrington, Centre for Neuro Skills Didra Cantu, MPA-HCM, Encompass Health Rehabilitation Hospital George Jenkins, Dignity Health, Bakersfield Memorial Hospital Ken Keller, Dignity Health, Bakersfield Memorial Hospital Kevin Burton, Klein DeNatale Goldner Lindsay Barnes, KGET-TV 17 Lisa Kreber, PhD, CBIS, Adventist Health Bakersfield Scott Salters, Cushman & Wakefield | Pacific Commercial Realty Advisors Sky Newton, SHRM-CP, Valley Strong Credit Union "The Heart and Stroke Walk is a fantastic chance for Kern County to come together as a united community, standing strong against heart disease and stroke," said Kelley Berry, executive director of the American Heart Association, Kern County. "We are immensely grateful for Lindsay's steadfast expertise, passion, and dedication to our mission. Leaders like her are crucial in our ongoing efforts to save lives and provide hope to families affected by heart disease and stroke." Funds raised go toward the American Heart Association’s work to advance lifesaving research, education and health for everyone. In Kern County, the Association has expanded access to CPR skills, connected local heart and stroke patients to the latest science-based treatments through its hospital programs and supported community members managing high blood pressure with tools and resources for better blood pressure control. Heart disease and stroke are largely preventable and how you eat, move and manage stress impacts your well-being, physically and mentally. Participants in the Heart and Stroke Walk gain access to resources, tools and activities to support both mental and physical well-being for employers and employees. Participants can register for the event at BakersfieldHeartWalk.com. Registrants can also create personal fundraising pages, download the Heart Walk mobile app and encourage family and friends to join. Companies interested in participating can contact Kelley Berry at Kelley.berry@heart.org. Centre for Neuro Skills, with seven locations across California and Texas, will be participating in American Heart Association’s local heart walk events across both states. Dr. Matt Ashley, Chief Medical Officer of Centre for Neuro Skills, currently serves as Board President on the Central Texas American Heart Association’s Board of Directors and will transition to Board Chair this July. As a former Heart Walk Chair in Austin, Texas, Dr. Matt Ashley remains committed to participating in and supporting the Central Texas Heart Walks. *** About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with the American Heart Association in Kern County on heart.org/southern-california, Facebook, Instagram, X or by calling 1-800-AHA-USA1. About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. For a video overview of CNS, visit our YouTube channel. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. ### Contact Details Landis Communications Inc. Andie Davis +1 415-766-8355 cns@landispr.com Company Website https://www.neuroskills.com/

May 20, 2025 08:01 AM Pacific Daylight Time

Image

1 2 3 4 5 ... 322